Overview
Mandolin provides an AI-driven automation platform for the specialty pharmaceutical market that automates back-office workflows around infused and injected drugs. Its AI agents plug into existing systems such as EHRs, payer portals, and manufacturer hubs to handle tasks like benefits verification, prior authorizations, insurance navigation, parsing documents, billing, and claims. The platform differentiates itself by directly integrating with current clinical and administrative systems and focusing on the specialty drug access workflow to speed up processes and improve revenue cycle management. Its goal is to shorten treatment delays from weeks to days, expand access to specialty therapies, and reduce costs for providers.
Work here?Claim your company
Simplify's take
What believers are saying
- Mandolin's site claims 250,000 patients annually across 700 clinic locations as of October 2026.
- TwelveStone said Mandolin cut tasks from days to under an hour after June 2025 deployment.
- The June 25, 2025 $40 million round gives Mandolin runway for rapid product expansion.
What critics are saying
- Payer portal changes and anti-bot controls can break Mandolin's core workflows overnight.
- Hospitals can switch to Epic, payer vendors, or in-house teams, compressing Mandolin's moat.
- If AI parsing misfiles clinical criteria, a claim denial or patient delay can trigger liability.
What makes Mandolin unique
- Mandolin automates referral-to-authorization workflows inside EHRs, not separate dashboards.
- It targets specialty drug access, where manual prior authorizations delay cancer and Alzheimer's treatment.
- Greylock-backed founders Will Yin and Rohit Rustagi built for infusion centers and specialty pharmacies.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards